QDELQuidelOrtho Corp
In Vitro & In Vivo Diagnostic Substances
- Revenue
- $2.7B
- 1.9% YoY
- Operating margin
- -33.7%
- 52% YoY
- EBITDA
- −$477M
- 68% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- —
- $2.4B net debt
- AI in 10-K
- —
Red flags 0 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear—Cash flow under 80% of net income
- Dilutive SBCClear2% of revenueOver 10% of revenue
- Payouts exceed cash flowClear0% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear0% of assetsOver 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | $1.7B | $1.7B | $3.3B | $2.8B | $2.7B | 1.9% |
| Operating income | $1.1B | $906M | $139M | −$2.0B | −$919M | 53% |
| Net income | $810M | $704M | $549M | −$2.1B | −$1.1B | 45% |
| Operating cash flow | $630M | $806M | $280M | $83M | $105M | 27% |
| Capex | $65M | $293M | $209M | $195M | $188M | 3.5% |
| Stock-based comp | $21M | $25M | $52M | $42M | $46M | 9.0% |
| Buybacks | $44M | $104M | $7M | $0 | $0 |
Deal filings
None.
13D filers
None on file.
Insider trading
No open-market trades in the last 12 months.
Pay vs performance
| Year | CEO total comp | Comp actually paid | TSR (indexed) | Peer TSR |
|---|---|---|---|---|
| FY2025 | — | — | 16 | 99 |
| FY2024 | — | — | 25 | 81 |
| FY2023 | — | — | 48 | 77 |
| FY2022 | — | — | 75 | 96 |